Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How can we symptomatically manage dizziness or risk of fall in older patients on enzalutamide ?
Related Questions
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?
Which patients do you consider to be good candidates for salvage local treatment after radiation therapy?
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?
What dose of prednisone do you prefer when treating CRPC vs CSPC with abiraterone?
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
How would you incorporate results from the PRESTO trial into your practice in light of greater use of PSMA PET scans for prostate cancer?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?
